NCT06659653View on ClinicalTrials.gov

Safety and Efficacy of PRG-2302 for Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Disease.

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 24, 2024

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2028

Conditions
Acute Lymphoblastic Leukemia
Interventions
DRUG

PRG2302

Dose group 1: with a dosage of 0.5x10\^6 (cells/kg) per dose Dose group 2: with a dosage of 1.0x10\^6 (cells/kg) per dose Dose group 3: with a dosage of 2.0x10\^6 (cells/kg) per dose

Trial Locations (1)

Unknown

RECRUITING

The First People's Hospital of Jingzhou, Jinzhou

All Listed Sponsors
collaborator

Shenzhen Pregene Biopharma Co., Ltd.

INDUSTRY

lead

Tan Jie

OTHER